ストックスクリーナーアプリを入手
84.66
0.90%
-0.72
Incyte Corp (INCY) 最新ニュース
What 14 Analyst Ratings Have To Say About Incyte - Benzinga
Sun Pharma Attacks Incyte Patents In Alopecia Drug Battle - Law360
INCY: JP Morgan Raises Price Target to $89, Maintains Neutral Ra - GuruFocus
Incyte (NASDAQ:INCY) Given Hold (C+) Rating at Weiss Ratings - MarketBeat
Can Incyte Corporation rally from current levels2025 Year in Review & Weekly Watchlist for Consistent Profits - newser.com
Is Incyte Corporation stock a safe buy before earnings2025 Technical Overview & Smart Investment Allocation Insights - newser.com
Incyte Faces Revenue Squeeze As Jakafi Patent Winds Down - Finimize
Incyte to Report Third Quarter Financial Results - Business Wire
Incyte stock rating downgraded to Perform by Oppenheimer - Investing.com
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Incyte Corporation (INCY) Appoints New Principal Financial Officer - GuruFocus
Is Incyte Corporation (ICY) stock a defensive play amid uncertaintyTrade Signal Summary & Free Fast Gain Swing Trade Alerts - newser.com
How to use Fibonacci retracement on Incyte CorporationPortfolio Update Summary & Target Return Focused Stock Picks - newser.com
Grimes & Company Inc. Has $12.26 Million Position in Incyte Corporation $INCY - MarketBeat
Price action breakdown for Incyte CorporationJuly 2025 PostEarnings & Step-by-Step Swing Trade Plans - newser.com
Legacy Trust Cuts Holdings in Incyte Corporation $INCY - MarketBeat
Published on: 2025-10-05 05:30:49 - newser.com
Why Incyte Corporation (ICY) stock is favored by hedge funds2025 Stock Rankings & Community Consensus Stock Picks - newser.com
How Incyte Corporation (ICY) stock reacts to stronger dollar2025 Price Targets & Free Long-Term Investment Growth Plans - newser.com
Institutional scanner results for Incyte Corporation2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com
Incyte Grants Equity Awards to New Chief Strategy Officer David Gardner - MyChesCo
Incyte Appoints Thomas Tray as Financial Officer - The Globe and Mail
Impact Investors Inc Has $209,000 Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte (NASDAQ:INCY) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Will Incyte's (INCY) New Strategy Team and CALR Antibody Hopes Reshape Its Long-Term Story? - simplywall.st
Incyte appoints Thomas Tray as principal financial officer - StreetInsider
Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism - MSN
Incyte (INCY) Is Up 5.7% After FDA Pediatric Opzelura Approval and Leadership Updates Has the Bull Case Changed? - simplywall.st
Incyte Names Dave Gardner Chief Strategy Officer Amid Leadership Transition - MyChesCo
Will Incyte Corporation stock outperform value stocksWeekly Gains Report & Community Consensus Trade Alerts - newser.com
Backtesting results for Incyte Corporation trading strategiesMarket Risk Summary & Community Consensus Picks - newser.com
Incyte Corporation stock hits 52-week high at 88.19 USD By Investing.com - Investing.com Australia
FDA Expands Approval of Incyte’s Opzelura to Treat Pediatric Atopic Dermatitis - MSN
Incyte Corporation stock hits 52-week high at 88.19 USD - Investing.com
Robeco Institutional Asset Management B.V. Has $162.51 Million Stock Position in Incyte Corporation $INCY - MarketBeat
2 Reasons to Like INCY and 1 to Stay Skeptical - The Globe and Mail
Lbp Am Sa Has $12.17 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Public Employees Retirement System of Ohio Buys 3,951 Shares of Incyte Corporation $INCY - MarketBeat
Poinciana Advisors Group LLC Makes New Investment in Incyte Corporation $INCY - MarketBeat
Will Incyte Corporation (ICY) stock see insider accumulationQuarterly Profit Report & AI Enhanced Market Trend Forecasts - newser.com
Patton Albertson Miller Group LLC Acquires 5,497 Shares of Incyte Corporation $INCY - MarketBeat
Patton Fund Management Inc. Takes $254,000 Position in Incyte Corporation $INCY - MarketBeat
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication - GlobeNewswire Inc.
Candlestick signals on Incyte Corporation stock todayMarket Performance Recap & Breakout Confirmation Alerts - newser.com
Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions - Yahoo Finance
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - MSN
Jim Cramer Calls Incyte “Way Too Cheap” - Yahoo Finance
Ruffer LLP Sells 9,988 Shares of Incyte Corporation $INCY - MarketBeat
Incyte (INCY) Gets a Hold from RBC Capital - The Globe and Mail
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 24, 2025 - biospace.com
RBC Capital Raises Price Target for Incyte (INCY) to USD 81 | IN - GuruFocus
Incyte stock price target raised to $81 from $72 at RBC Capital - Investing.com
Guggenheim Reaffirms "Neutral" Rating for Incyte (NASDAQ:INCY) - MarketBeat
Incyte’s Povorcitinib Shows Sustained Efficacy in Phase 3 HS Trial, Supports 2025/2026 Regulatory Submissions - Insider Monkey
3.34%
1.17%
大文字化:
|
ボリューム (24 時間):